JPY 8340.0
(12.7%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 9.63 Million JPY | -54.16% |
2022 | 21.01 Million JPY | 97.24% |
2021 | 10.65 Million JPY | 7619.57% |
2020 | 138 Thousand JPY | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q1 | -17.62 Million JPY | -458.58% |
2023 FY | 9.63 Million JPY | -54.16% |
2023 Q4 | 4.91 Million JPY | 860.16% |
2023 Q3 | 512 Thousand JPY | -83.25% |
2023 Q1 | 1.14 Million JPY | -91.54% |
2023 Q2 | 3.05 Million JPY | 166.43% |
2022 FY | 21.01 Million JPY | 97.24% |
2022 Q4 | 13.55 Million JPY | 0.0% |
2021 FY | 10.65 Million JPY | 7619.57% |
2020 FY | 138 Thousand JPY | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
KOHJIN BIO CO LTD | 1.88 Billion JPY | 99.488% |
PRISM BioLab Co.,LTD | 80.3 Million JPY | 88.007% |
GNI Group Ltd. | 22.43 Billion JPY | 99.957% |
Linical Co., Ltd. | 3.77 Billion JPY | 99.745% |
Trans Genic Inc. | 2.24 Billion JPY | 99.572% |
MEDINET Co., Ltd. | 98.25 Million JPY | 90.198% |
Soiken Holdings Inc. | 2.48 Billion JPY | 99.612% |
Cytori Cell Research Institute, Inc. | 1.29 Billion JPY | 99.255% |
AnGes, Inc. | -3.06 Billion JPY | 100.314% |
OncoTherapy Science, Inc. | -177.71 Million JPY | 105.419% |
Nxera Pharma Co., Ltd. | 9.66 Billion JPY | 99.9% |
Immuno-Biological Laboratories Co., Ltd. | 517.29 Million JPY | 98.138% |
NanoCarrier Co., Ltd. | 110.95 Million JPY | 91.32% |
Carna Biosciences, Inc. | 1.45 Billion JPY | 99.336% |
CanBas Co., Ltd. | -984 Million JPY | 100.979% |
D. Western Therapeutics Institute, Inc. | 391.69 Million JPY | 97.541% |
RaQualia Pharma Inc. | 1.65 Billion JPY | 99.418% |
Chiome Bioscience Inc. | 398.59 Million JPY | 97.584% |
Kidswell Bio Corporation | 1.03 Billion JPY | 99.073% |
PeptiDream Inc. | 17.21 Billion JPY | 99.944% |
Oncolys BioPharma Inc. | 30.6 Million JPY | 68.531% |
Ribomic Inc. | -10.5 Million JPY | 191.706% |
SanBio Company Limited | -14.5 Million JPY | 166.402% |
Healios K.K. | 108 Million JPY | 91.082% |
BrightPath Biotherapeutics Co., Ltd. | -341 Thousand JPY | 2924.34% |
Kubota Pharmaceutical Holdings Co., Ltd. | -59.04 Million JPY | 116.311% |
Delta-Fly Pharma, Inc. | -1.51 Million JPY | 736.971% |
StemRIM | -44.34 Million JPY | 121.716% |
CellSource Co., Ltd. | 3.18 Billion JPY | 99.698% |
FunPep Company Limited | -680.28 Million JPY | 101.416% |
Kringle Pharma, Inc. | 69.25 Million JPY | 86.092% |
Stella Pharma Corporation | 217.29 Million JPY | 95.568% |
TMS Co., Ltd. | -6.95 Million JPY | 238.576% |
Noile-Immune Biotech Inc. | 314.56 Million JPY | 96.938% |
K Pharma,Inc. | 910 Million JPY | 98.942% |
Takara Bio Inc. | 25.45 Billion JPY | 99.962% |
ReproCELL Incorporated | 1.1 Billion JPY | 99.128% |
PhoenixBio Co., Ltd. | 1.19 Billion JPY | 99.194% |
StemCell Institute Inc. | 1.57 Billion JPY | 99.389% |
Japan Tissue Engineering Co., Ltd. | 1.66 Billion JPY | 99.422% |
CellSeed Inc. | 107.15 Million JPY | 91.012% |